PURPOSE: To report on the anatomic and visual acuity response after intravitreal bevacizumab injection in patients with macular edema due to non-ischemic central retinal vein occlusion (CRVO). METHODS: In a retrospective study, 21 consecutive patients (21 eyes) with non-ischemic CRVO underwent, on average, 3.7 intravitreal bevacizumab injections (1.25 mg). Ophthalmic examination included best corrected visual acuity (BCVA) and central retinal thickness (CRT) at baseline and follow-up visits. Fluorescein angiography was performed at baseline and at follow-up visits if needed. Primary outcomes were change of BCVA and CRT. RESULTS: The follow-up period for all of the included patients was 12 months. The mean BCVA was unchanged at the 12-month examination (baseline: 20/160; 12 months: 20/160) (P = 0.771). The mean CRT decreased from 780 microm (standard deviation [SD] +/- 324 microm) at the baseline to a mean of 462 microm (SD +/- 248 microm) at 12 months (P < 0.05). CONCLUSION: Intravitreal bevacizumab resulted in a significant decrease in CRT without significant improvement of visual acuity in patients with non-ischemic CRVO after a follow-up of 12 months.
PURPOSE: To report on the anatomic and visual acuity response after intravitreal bevacizumab injection in patients with macular edema due to non-ischemic central retinal vein occlusion (CRVO). METHODS: In a retrospective study, 21 consecutive patients (21 eyes) with non-ischemic CRVO underwent, on average, 3.7 intravitreal bevacizumab injections (1.25 mg). Ophthalmic examination included best corrected visual acuity (BCVA) and central retinal thickness (CRT) at baseline and follow-up visits. Fluorescein angiography was performed at baseline and at follow-up visits if needed. Primary outcomes were change of BCVA and CRT. RESULTS: The follow-up period for all of the included patients was 12 months. The mean BCVA was unchanged at the 12-month examination (baseline: 20/160; 12 months: 20/160) (P = 0.771). The mean CRT decreased from 780 microm (standard deviation [SD] +/- 324 microm) at the baseline to a mean of 462 microm (SD +/- 248 microm) at 12 months (P < 0.05). CONCLUSION: Intravitreal bevacizumab resulted in a significant decrease in CRT without significant improvement of visual acuity in patients with non-ischemic CRVO after a follow-up of 12 months.
Authors: Diana Iturralde; Richard F Spaide; Catherine B Meyerle; Jay M Klancnik; Lawrence A Yannuzzi; Yale L Fisher; John Sorenson; Jason S Slakter; K Bailey Freund; Michael Cooney; Howard F Fine Journal: Retina Date: 2006-03 Impact factor: 4.256
Authors: Sivakami A Pai; Rohit Shetty; Priya B Vijayan; G Venkatasubramaniam; Naresh K Yadav; Bhujang K Shetty; Rajesh B Babu; Kannan M Narayana Journal: Am J Ophthalmol Date: 2007-02-15 Impact factor: 5.258
Authors: Rogério A Costa; Rodrigo Jorge; Daniela Calucci; Luiz A Melo; José A Cardillo; Ingrid U Scott Journal: Retina Date: 2007-02 Impact factor: 4.256
Authors: Siegfried G Priglinger; Armin H Wolf; Thomas C Kreutzer; Daniel Kook; Anja Hofer; Rupert W Strauss; Claudia S Alge; Christian Kunze; Christos Haritoglou; Anselm Kampik Journal: Retina Date: 2007-10 Impact factor: 4.256
Authors: Jason Hsu; Richard S Kaiser; Arunan Sivalingam; Prema Abraham; Mitchell S Fineman; Michael A Samuel; James F Vander; Carl D Regillo; Allen C Ho Journal: Retina Date: 2007-10 Impact factor: 4.256
Authors: Yoko Matsumoto; K Bailey Freund; Enrico Peiretti; Michael J Cooney; Daniela C A C Ferrara; Lawrence A Yannuzzi Journal: Retina Date: 2007 Apr-May Impact factor: 4.256
Authors: Ingrid U Scott; Paul C VanVeldhuisen; Michael S Ip; Barbara A Blodi; Neal L Oden; Maria Figueroa; Pravin U Dugel Journal: Ophthalmology Date: 2016-11-15 Impact factor: 12.079
Authors: Motasem Al-Latayfeh; Paolo S Silva; Jennifer K Sun; Lloyd Paul Aiello Journal: Cold Spring Harb Perspect Med Date: 2012-06 Impact factor: 6.915
Authors: Francis Char DeCroos; Bozho Todorich; Rayan Alshareef; Mohammed Khuthaila; Sharon Fekrat; Allen C Ho; Carl D Regillo; Marc J Spirn Journal: J Ophthalmic Vis Res Date: 2014 Oct-Dec
Authors: Olga Dratviman-Storobinsky; Bat-Chen R Avraham-Lubin; Murat Hasanreisoglu; Nitza Goldenberg-Cohen Journal: Mol Vis Date: 2009-11-13 Impact factor: 2.367
Authors: Christina L Ryu; Adrian Elfersy; Uday Desai; Thomas Hessburg; Paul Edwards; Hua Gao Journal: J Ophthalmol Date: 2014-04-01 Impact factor: 1.909